Fennec's PEDMARK hits primary endpoint in Japan Phase 2, 24% hearing loss vs 56.4%

FENNEC PHARMACEUTICALS INC.

Phase 2 STS-J01 met primary endpoint: ASHA-defined hearing loss 24.0% (6/25) vs 56.4% historical benchmark (P=0.001).
No Grade 3/4 hearing loss by Brock criteria; 84.0% Grade 0 hearing loss.
Objective tumor responses in 23/24 evaluable patients (95.8%), no interference with cisplatin antitumor activity.
Company pursuing Japanese registration and exploring partnering/licensing for PEDMARK.
Safety consistent with known profile; no serious adverse events attributed to PEDMARK.

Featured in Daily 8-K Digest

Selected #10 for 2026-09-17. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.